Physician profile
Philip C Hoffman
NPI 1700949229
$117,265.93
in general payments reported to CMS, 2019-2025
18 companies · $30K in 2025
The $30K reported for 2025 was more than what 94% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.96 · 2021: $4,212 · 2022: $33K · 2023: $20K · 2024: $30K · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $76K · Travel and Lodging: $3,221 · Food and Beverage: $479.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $76,221.30 |
| Travel and Lodging | $3,220.97 |
| Food and Beverage | $479.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $23,075.00 | 2022-2023 | Jemperli |
| Astrazeneca Pharmaceuticals LP | $15,070.00 | 2023-2024 | Imfinzi, Lynparza |
| Beigene USA, INC. | $10,791.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $9,494.49 | 2024 | |
| Astrazeneca Uk Limited | $8,776.26 | 2025 | |
| Merck Sharp & Dohme LLC | $7,893.86 | 2024 | Keytruda |
| Genentech, INC. | $7,528.35 | 2025 | Columvi |
| Urogen Pharma, INC. | $6,919.34 | 2025 | |
| Pfizer INC. | $6,661.96 | 2019-2025 | |
| Acrotech Biopharma INC. | $5,850.00 | 2023 | Beleodaq |
| Janssen Research & Development, LLC | $5,525.00 | 2024 | Carvykti |
| Tg Therapeutics, INC. | $5,400.00 | 2022 | |
| Eli Lilly and Company | $4,200.00 | 2021 | |
| Medtronic, INC. | $39.14 | 2024 | Signia |
| Alexion Pharmaceuticals, INC. | $29.61 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $11.92 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.